# Harmony Biosciences Posts Record Q2 WAKIX Revenue of $261M and CFO Departure

> news · REPORTED · 2026-07-16

Harmony Biosciences reported preliminary Q2 2026 WAKIX net product revenue of approximately $261 million, a 30% year-over-year increase and a new quarterly record, while reaffirming full-year 2026 net revenue guidance of $1.0 to $1.04 billion. Concurrently, CFO Glenn Reicin stepped down effective July 16, 2026, with SVP and Controller Stephen Mollichella named Interim Principal Financial Officer.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases, anchored by WAKIX for narcolepsy.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.tipranks.com/news/company-announcements/harmony-biosciences-posts-record-q2-wakix-revenue

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.